Highlight
• HMI-115, a human monoclonal antibody that non-competitively blocks the prolactin receptor, produced dose-dependent pain reductions in a global phase II proof-of-concept trial for endometriosis-associated pain (premeno women).
• At 240 mg every 2 weeks subcutaneously for 12 weeks, dysmenorrhea NRS fell by 41.6% versus 18.6% with placebo; non-menstrual pelvic pain also improved and effects persisted through a 25-week follow-up.
